% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Merz:127124,
      author       = {M. Merz$^*$ and J. Ritsch and C. Kunz$^*$ and B. Wagner and
                      S. Sauer and D. Hose and T. Moehler and S. Delorme$^*$ and
                      H. Goldschmidt and C. Zechmann and J. Hillengass$^*$},
      title        = {{D}ynamic contrast-enhanced magnetic resonance imaging for
                      assessment of antiangiogenic treatment effects in multiple
                      myeloma.},
      journal      = {Clinical cancer research},
      volume       = {21},
      number       = {1},
      issn         = {1557-3265},
      address      = {Philadelphia, Pa. [u.a.]},
      publisher    = {AACR},
      reportid     = {DKFZ-2017-03150},
      pages        = {106 - 112},
      year         = {2015},
      abstract     = {To noninvasively assess bone marrow microcirculation before
                      and after therapy in patients with newly diagnosed multiple
                      myeloma with dynamic contrast-enhanced MRI
                      (DCE-MRI).Ninety-six patients received DCE-MRI before and
                      after primary treatment for newly diagnosed multiple
                      myeloma. For the 91 evaluable patients, treatment consisted
                      of high-dose therapy (HDT) with autologous stem cell
                      transplantation (ASCT) in 82 patients and chemotherapy
                      without ASCT in 9 patients. In addition, 33 healthy
                      volunteers were imaged as the control group. Analysis of
                      DCE-MRI was performed according to the two-compartment model
                      by Brix to quantify amplitude A (associated with blood
                      volume) and exchange rate constant kep (reflecting vessel
                      permeability and perfusion).Nonresponders showed
                      significantly higher A-values before the start of therapy
                      compared with responders (P = 0.02). In both responders and
                      nonresponders to therapy, A-values dropped significantly (P
                      = 0.004 and <0.001, respectively) after primary therapy,
                      whereas lower values for kep were found only in responders
                      (P < 0.001). Depth of remission was significantly correlated
                      to decreased bone marrow microcirculation: Patients in near
                      complete response (nCR) or complete remission (CR) after
                      treatment showed significantly lower values for A compared
                      with patients not achieving nCR+CR. The application of HDT
                      or novel agents had no significant effect on DCE-MRI
                      parameters after therapy, although patients treated with
                      novel agents more often achieved nCR+CR $(42\%/12.5\%;$ P <
                      0.002). Higher kep-values at second MRI were positively
                      correlated to shorter overall survival (HR 3.53; $95\%$
                      confidence intervals, 1.21-10.33; P = 0.02).Parameters from
                      DCE-MRI are correlated to remission after primary therapy
                      and outcome in newly diagnosed multiple myeloma.},
      keywords     = {Angiogenesis Inhibitors (NLM Chemicals)},
      cin          = {E010 / C060},
      ddc          = {610},
      cid          = {I:(DE-He78)E010-20160331 / I:(DE-He78)C060-20160331},
      pnm          = {315 - Imaging and radiooncology (POF3-315)},
      pid          = {G:(DE-HGF)POF3-315},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:25351744},
      doi          = {10.1158/1078-0432.CCR-14-1029},
      url          = {https://inrepo02.dkfz.de/record/127124},
}